Loading…
Vertex Pharmaceuticals Incorporated is projected to rise to $564.21 by 2027, a +29% move from its current price of $437.22. VRTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $432.61 | $437.38 | $442.20 | +0.04% |
| May 30 | $430.80 | $437.54 | $444.38 | +0.07% |
| May 31 | $429.46 | $437.70 | $446.09 | +0.11% |
| Jun 1 | $428.36 | $437.86 | $447.56 | +0.15% |
| Jun 2 | $427.40 | $438.01 | $448.89 | +0.18% |
| Jun 3 | $426.56 | $438.17 | $450.10 | +0.22% |
| Jun 4 | $425.80 | $438.33 | $451.24 | +0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $425.80 | $438.33 | $451.24 | +0.25% |
| Week 2 | $421.78 | $439.45 | $457.85 | +0.51% |
| Week 3 | $418.97 | $440.57 | $463.27 | +0.77% |
| Week 4 | $416.79 | $441.69 | $468.08 | +1.02% |
| Week 5 | $414.99 | $442.81 | $472.49 | +1.28% |
| Week 6 | $413.48 | $443.94 | $476.64 | +1.54% |
| Week 7 | $412.18 | $445.07 | $480.58 | +1.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.
The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals Incorporated (VRTX) is a healthcare company with a current price of $434.52 and a market capitalization of $110.28B. It is ranked 140. The stock operates within the healthcare space and has a 30-day technical picture characterized by neutral sentiment, with RSI14 at 50, SMA50 at $440.29, and SMA200 at $434.75.
Near-term support sits at $423.24 and resistance at $453.06, with a 30-day price range from $402.43 to $469.17.
A major floor 6.7% below — a decisive break under it would weaken the trend.
The nearest floor, 3.2% below — buyers have tended to step in here.
The nearest ceiling, 3.6% above — a clean break opens room to run.
A major ceiling 14.2% above — clearing it would confirm fresh momentum.
Key VRTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VRTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $434.33 | Buy | $435.86 | Buy |
| MA 10 | $438.30 | Sell | $435.93 | Buy |
| MA 20 | $433.88 | Buy | $435.99 | Buy |
| MA 50 | $439.04 | Sell | $440.97 | Sell |
| MA 100 | $454.39 | Sell | $444.87 | Sell |
| MA 200 | $435.40 | Buy | $445.03 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.38 | Neutral |
| Stoch RSI (14) | 45.03 | Neutral |
| CCI (20) | 34.98 | Neutral |
| Williams %R (14) | -56.45 | Info |
| MACD (12,26,9) | 0.51 | Buy |
| ROC (12) | 1.72 | Buy |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 43.55 | Neutral |
| TRIX (15) | -0.04 | Sell |
| Awesome (5,34) | -0.92 | Sell |
| Ultimate (7,14,28) | 52.95 | Neutral |
| Momentum (10) | -11.07 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 434.49 | Buy |
| ADX (14) | 10.17 | Neutral |
| ATR (14) | 4.21 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 50 and moving averages showing a tight corridor around the current price (SMA50 $440.29; SMA200 $434.75). This configuration reflects a balanced near-term posture with limited directional conviction.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $423.24 | $437.22 | $559.95 | 0% | Neutral | |
| $460.92 | $564.21 | $722.92 | +29% | Bullish | |
| $551.75 | $687.73 | $904.21 | +57% | Bullish | |
| $564.50 | $714.27 | $958.65 | +63% | Bullish | |
| $624.75 | $801.03 | $1,094.12 | +83% | Bullish | |
| $659.61 | $855.95 | $1,187.35 | +96% | Bullish | |
| $672.25 | $882.12 | $1,240.85 | +102% | Bullish | |
| $784.39 | $1,040.03 | $1,481.72 | +138% | Bullish | |
| $886.66 | $1,187.25 | $1,711.50 | +172% | Bullish | |
| $961.56 | $1,299.66 | $1,894.22 | +197% | Bullish | |
| $1,355.49 | $1,910.55 | $2,917.24 | +337% | Bullish | |
| $2,131.14 | $3,221.03 | $5,270.48 | +637% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $423.24 | $437.22 | $511.98 | +0.00% |
| June 2026 | $383.89 | $447.83 | $532.56 | +2.43% |
| July 2026 | $385.19 | $451.94 | $542.52 | +0.92% |
| August 2026 | $374.87 | $441.80 | $534.21 | -2.24% |
| September 2026 | $373.20 | $441.47 | $536.98 | -0.08% |
| October 2026 | $381.40 | $452.71 | $553.63 | +2.55% |
| November 2026 | $381.28 | $453.93 | $557.72 | +0.27% |
| December 2026 | $380.01 | $453.72 | $559.95 | -0.05% |
Click any year to see its month-by-month VRTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Vertex Pharmaceuticals Incorporated's 2026 outlook centres on $437.22, within a $423.24 to $559.95 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, VRTX could reach as high as $722.92, with a base case around $564.21 and support toward $460.92 — roughly +29% from $437.22. Momentum favours further upside here.
Expect VRTX to range from $551.75 to $904.21 through 2028. The $687.73 average target implies a +57% move from current prices. That is up +22% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The VRTX price prediction for 2029 points to an average of $714.27 (low $564.50, high $958.65) — a potential gain of +63% on today's $437.22. Momentum favours further upside here.
In 2030, VRTX is projected to trade between $624.75 and $1,094.12, averaging $801.03 — a potential gain of +83% from today's $437.22. That is up +12% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Vertex Pharmaceuticals Incorporated's 2031 outlook centres on $855.95, within a $659.61 to $1,187.35 range. That is up +7% on the projected 2030 average. That marks a +96% change versus current levels. Momentum favours further upside here.
By 2032, VRTX could reach as high as $1,240.85, with a base case around $882.12 and support toward $672.25 — roughly +102% from $437.22. Buyers look set to stay in control over this stretch.
Expect VRTX to range from $784.39 to $1,481.72 through 2033. The $1,040.03 average target implies a +138% move from current prices. That is up +18% on the projected 2032 average. Momentum favours further upside here.
The VRTX price prediction for 2034 points to an average of $1,187.25 (low $886.66, high $1,711.50) — a potential gain of +172% on today's $437.22. Buyers look set to stay in control over this stretch.
In 2035, VRTX is projected to trade between $961.56 and $1,894.22, averaging $1,299.66 — a potential gain of +197% from today's $437.22. That is up +9% on the projected 2034 average. Momentum favours further upside here.
Vertex Pharmaceuticals Incorporated's 2040 outlook centres on $1,910.55, within a $1,355.49 to $2,917.24 range. That is up +47% on the projected 2035 average. That marks a +337% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, VRTX could reach as high as $5,270.48, with a base case around $3,221.03 and support toward $2,131.14 — roughly +637% from $437.22. Momentum favours further upside here.
Investing $1,000 in VRTX today (≈ 2.287178 VRTX) could be worth
$7,367.08
+$6,367.08 (+637%) by 2050 · US Dollar
Based on the average projected VRTX price of $3,221.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VRTXwould be worth at today's price.
$1,000 invested in VRTX on May 27, 2025 (≈ 2.242152 VRTX) would be worth
$980.31
-$19.69 (-2.0%) today · 0.98× · US Dollar
Based on a VRTX entry price of $446 vs. today's $437.22.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $430.44 | $1,015.75 | +1.6% |
| 1 month ago | $426.01 | $1,026.31 | +2.6% |
| 3 months ago | $480.13 | $910.63 | -8.9% |
| 6 months ago | $433.61 | $1,008.33 | +0.8% |
| 1 year ago | $446 | $980.31 | -2.0% |
| All time (5.0y) ago | $209.67 | $2,085.28 | +108.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VRTX forecast.
Our base-case forecast reaches $870.00 around 2032.
Implied market cap at $870.00: $220.81B
The multi-year forecast leans bullish over the period through 2050. In 2027 the average price is forecast at $556.63 with a min of $454.60 and a max of $713.49, and a 28.1 ROI; by 2028 the average rises to $670.94 with a max of $882.41 and a min of $538.17, ROI 54.4. The path remains bullish through 2029 (avg $695.96; max $934.31; min $549.92; ROI 60.2) and into 2030 (avg $780.02; max $1,065.65; min $608.26; ROI 79.5).
By 2033 the average is forecast at $998.89 (max $1,423.35; min $753.26; ROI 129.9), and by 2034 the average reaches $1,133.45 (max $1,634.19; min $846.37; ROI 160.8), with 2035 average $1,240.97 (min $918.02; max $1,808.95; ROI 185.6). The forecast then accelerates to 2040, with an average of $1,795.56 (min $1,273.77; max $2,741.96; ROI 313.2) and culminates in 2050 at an average of $3,028.43 (min $2,003.53; max $4,955.73; ROI 597), all reflecting a bullish sentiment. These are estimates and not guarantees, and they illustrate potential upside alongside the inherent uncertainty of long-range projections.
Tap a question to reveal the answer.
Avg $780.02; max $1,065.65; min $608.26; ROI 79.5; sentiment BULLISH.
The forecast indicates bullish sentiment from 2027 onward, with rising averages and higher max values (e.g., 2027 avg $556.63 and 2050 avg $3,028.43, ROI 597), though 2026 shows a neutral stance with avg $434.52 and ROI 0. These figures are estimates, not guarantees.
Yes. The 2033 forecast shows an average of $998.89 and a max of $1,423.35, suggesting a pathway to around $1,000 within that horizon.
Annualized volatility is 20%.
Vertex Pharmaceuticals Incorporated Community Discussion
0Share your Vertex Pharmaceuticals Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.